Bernat Olle, Vedanta Biosciences CEO

Pfiz­er-backed Vedan­ta Bio­sciences lands $106M for PhI­II in C. diff, PhII in IBD

Vedan­ta Bio­sciences has se­cured the cash it needs to run a Phase III in Clostrid­ioides dif­fi­cile and a mid-stage tri­al in ul­cer­a­tive col­i­tis, with run­way …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.